.22
  Price1.95%   +0.0042
(Pre-market: .22 +0 +0.00%)
May-11-22 02:30AM Calithera Biosciences (CALA) Q1 2022 Earnings Call TranscriptThe Motley Fool
May-10-22 04:05AM Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent HighlightsGlobeNewswire Inc.
09:23AM The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO LeavesBenzinga
Apr-21-22 05:00AM Best Penny Stocks to Buy Under $1 Now? 3 to Watch in MayPennyStocks
Apr-08-22 01:01AM Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal CompoundsGlobeNewswire Inc.
Apr-04-22 08:09AM 10 Biggest Price Target Changes For MondayBenzinga
Apr-01-22 11:00AM Calithera Biosciences (CALA) Q4 2021 Earnings Call TranscriptThe Motley Fool
Mar-31-22 08:14AM The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 ShortfallBenzinga
Mar-30-22 02:00AM Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common StockGlobeNewswire Inc.
Mar-29-22 04:01AM Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common StockGlobeNewswire Inc.
Mar-28-22 05:05AM 3 Hot Meme Penny Stocks to Watch Under $3 Right NowPennyStocks
Feb-16-22 07:00AM Calithera to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswire Inc.
Nov-29-21 08:40AM Do Options Traders Know Something About Calithera Biosciences (CALA) Stock We Don't?Zacks Investment Research
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839 in cell renal cell carcinoma. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Cap:    |  Volume (24h):